Co-Inventors
Yiu, Ying
Myers, Lara
Weissman, Irving
Hasenkrug, Kim
Therapeutic Areas
Oncology
Infectious Disease
Immunology
Research Products
Human Cell Lines
Antibodies
The technology revolves around the discovery of SIRPα (Signal Regulatory Protein alpha) expression on CD8+ T cells as a novel biomarker for assessing T cell functionality during immune exhaustion, a state commonly induced by chronic infections and cancer. The unique expression profile of SIRPα on a subset of functional CD8+ T cells that retain cytotoxic capabilities despite an exhausted phenotype opens new avenues for therapeutic interventions. By counterbalancing inhibitory signals with costimulatory receptors, these SIRPα+ CD8+ T cells maintain their proliferative and IFN-gamma secreting abilities, offering a potential target for therapies aimed at reinvigorating T cell responses. Evaluating patients for SIRPα expression could enable the identification of individuals likely to benefit from checkpoint inhibitor treatments and aid in monitoring the efficacy of such therapies, significantly impacting the management of chronic infections and cancer immunotherapy.
Commercial Applications
The potential applications of SIRPα expression profiling are vast and transformative, particularly within personalized medicine. In oncology, assessing SIRPα levels could refine patient selection for immunotherapies, leading to improved response rates and personalized treatment plans. For chronic infectious diseases, this biomarker could predict the durability of the immune response, guiding vaccine development and therapeutic interventions.
Competitive Advantages
The identification of SIRPα as a biomarker for functionally resilient CD8+ T cells during immunological exhaustion offers a competitive advantage in the field of precision immunotherapy. This discovery enables the stratification of patients who are most likely to respond to checkpoint inhibitors, thus optimizing treatment efficacy and potentially reducing the costs associated with less targeted therapies. Moreover, the ability to monitor SIRPα expression provides a real-time assessment of treatment efficacy, allowing for timely adjustments to therapeutic strategies. This biomarker also opens the possibility for the development of novel therapeutic agents that can specifically enhance the function of SIRPα+ CD8+ T cells, leading to improved outcomes for patients with chronic infections or cancer. Furthermore, as a prognostic tool, SIRPα expression can guide clinical decision-making, moving towards more personalized and effective care, and setting this technology apart in a rapidly evolving oncology landscape.
